



Office de la Propriété

Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2429636 C 2013/02/05

(11)(21) **2 429 636**

(12) **BREVET CANADIEN**
CANADIAN PATENT

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 2001/12/27
(87) Date publication PCT/PCT Publication Date: 2002/07/11
(45) Date de délivrance/Issue Date: 2013/02/05
(85) Entrée phase nationale/National Entry: 2003/05/22
(86) N° demande PCT/PCT Application No.: SE 2001/002908
(87) N° publication PCT/PCT Publication No.: 2002/053595
(30) Priorité/Priority: 2000/12/29 (SE0004892-6)

(51) Cl.Int./Int.Cl. *C07K 16/16* (2006.01),
A61K 39/36 (2006.01), *A61K 39/395* (2006.01),
G01N 33/563 (2006.01), *G01N 33/564* (2006.01),
G01N 33/68 (2006.01)

(72) Inventeurs/Inventors:
FLICKER, SABINE, AT;
STEINBERGER, PETER, AT;
KRAFT, DIETRICH, AT;
VALENTA, RUDOLF, AT

(73) Propriétaire/Owner:
PHADIA AB, SE

(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : IGE-FABS SPECIFIQUE AUX ALLERGENES DU GROUPE 2, MOLECULES IGG ET LEUR UTILISATION
(54) Title: GROUP 2 ALLERGEN SPECIFIC IGE-FABS AND IGG MOLECULES AND USE THEREOF

(57) Abrégé/Abstract:

The present invention relates to group 2 allergen specific IgE-Fabs and whole Ig molecules as well as use thereof. More precisely, the present invention relates to grass pollen specific IgE-Fabs (Phl p2) and reagents, kits and vaccines comprising these. The invention also relates to use of group 2 specific IgE-Fabs and whole Ig for, inter alia, diagnosis, therapy and prevention of type I allergy.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
11 July 2002 (11.07.2002)

PCT

(10) International Publication Number
WO 02/053595 A1(51) International Patent Classification⁷: C07K 16/16, A61K 39/395, 39/36, G01N 33/563, 33/564

(74) Agent: DR LUDWIG BRANN PATENTBYRÅ AB; Box 1344, S-751 43 Uppsala (SE).

(21) International Application Number: PCT/SE01/02908

(81) Designated States (national): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EC, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 27 December 2001 (27.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 0004892-6 29 December 2000 (29.12.2000) SE

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): PHARMACIA DIAGNOSTICS AB [SE/SE]; S-751 82 Uppsala (SE).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): FLICKER, Sabine [AT/AT]; Speckbackergasse 44/2/7, A-1160 Vienna (AT). STEINBERGER, Peter [AT/AT]; Wilhelminenstrasse 93/14/12, A-1160 Vienna (AT). KRAFT, Dietrich [AT/AT]; Rebenweg 1/18/1, A-1170 Vienna (AT). VALENTA, Rudolf [AT/AT]; Beethovenstrasse 18, A-2604 Theresienfeld (AT).

WO 02/053595 A1

(54) Title: GROUP 2 ALLERGEN SPECIFIC IGE-FABS AND IGG MOLECULES AND USE THEREOF

(57) Abstract: The present invention relates to group 2 allergen specific IgE-Fabs and whole Ig molecules as well as use thereof. More precisely, the present invention relates to grass pollen specific IgE-Fabs (Phl p2) and reagents, kits and vaccines comprising these. The invention also relates to use of group 2 specific IgE-Fabs and whole Ig for, inter alia, diagnosis, therapy and prevention of type I allergy.

GROUP 2 ALLERGEN SPECIFIC IGE-FABS AND IGG MOLECULES AND USE THEREOF

Field of the invention

The present invention relates to group 2 allergen specific IgE-Fabs and use thereof. More precisely, the present invention relates to grass pollen specific IgE-Fabs (Phl p2) and reagents, kits and vaccines comprising these. The invention also relates to use of group 2 specific IgE-Fabs for, *inter alia*, diagnosis, therapy and prevention of type I allergy.

Background of the invention

Almost 500 million individuals suffer from Type I allergy, a genetically determined hypersensitivity disease which is based on the formation of IgE antibodies against *per se* harmless antigens (i. e., allergens) (1). The symptoms of Type allergy (allergic rhinitis, conjunctivitis and allergic asthma) are mainly caused by the crosslinking of effector-cell bound specific IgE antibodies and the consecutive release of biological mediators (e.g., histamine, leukotriens) (2).

Grasses and corn are distributed worldwide, produce large amounts of pollen which become easily airborn and therefore belong to the most important allergen sources. More than 40% of allergic patients are sensitized against grass pollen allergens of which group 2 allergens represent one of the most frequently recognized allergens (3, 4). Group 2 allergens occur in pollen of many grass species as highly homologous proteins with a molecular weight of approximately 10-11 kDa. Approximately 70% of grass pollen allergic people are cross-sensitized to group 2 allergens which is due to sequence, structural, and immunological similarities of group 2 allergens from different grass and corn species (5-7). Recombinant Phl p 2 from timothy grass has been produced as immunologically active recombinant protein which equals the properties of the natural allergen (6). Moreover the three dimensional

structure of rPhI p 2 has been recently determined by NMR analysis and was found to resemble structural features of an immunoglobulin-like domain (8).

Specific therapy of Type I allergy can be achieved in principle by active and passive vaccination. Active vaccination is achieved by specific immunotherapy in order to induce unresponsiveness towards allergens. Although successfully practised since 1911, the immunologically mechanisms of specific immunotherapy are not completely understood (9, 10). Induction of blocking antibodies of the IgG class which interfere with the IgE allergen interaction, modulation of T cell and effector cell responses and generation of tolerance are discussed as possible mechanisms (11). In contrast to active vaccination, passive vaccination is based on the transfer of protective immunoglobulins and represents a routine treatment for many infectious diseases (e.g., hepatitis). The therapeutical efficacy of "passive vaccination" for the treatment of Type I allergy has been demonstrated by classical experiments more than 60 years ago. In 1935 Cooke and colleagues reported cure of a hayfever patient by transfer of blood from a patient who had been successfully treated by specific immunotherapy (12). A few years later Loveless showed that the protective effects reported by Cooke are due to blocking antibodies (13). There are several arguments why blocking antibodies may be useful for passive therapy of Type I allergy. First, IgE is the least abundant class of immunoglobulins which could be easily competed. Second, allergic reactions occur in target organs (nose, eyes, lung, skin) where it would be easy to apply blocking antibodies or other competitors of the IgE-allergen interaction avoiding the need of systemic application. The application of the "passive vaccination concept" for treatment of Type I allergy requires however progress in the field of allergen characterization and antibody technology.

Summary of the invention

The present invention provides human IgE-Fabs suitable for diagnosis and immunotherapy of type I allergy.

In a first aspect, the invention provides group 2 allergen (i.e. pollen allergen from different grass and corn species) specific human IgE Fabs having the amino acid sequences as shown in SEQ ID No 2A-B or essentially homologous variants thereof.

In a second aspect, the invention provides group 2 allergen specific human IgE Fabs encoded by the nucleic acid sequences as shown in SEQ ID No 1A-B or essentially homologous variants thereof. For example, variants caused by the degeneracy of the genetic code. The present invention also provides group 2 allergen specific human IgG comprising the variable regions of the above IgE Fabs. Preferably, the whole Ig molecules of the invention are of IgG1 subtype. The present inventors have grafted variable regions of the IgE Fabs of the invention onto human IgG1 using a known vector system. Surprisingly, these complete IgG1 antibodies strongly suppress Phl p2-induced degranulation of patients basophils which indicates their potential for clinical application.

The IgE-Fabs and/or whole Ig according to the invention are directed against Phl p 2, i.e. pollen from timothy grass but cross-react with several other pollen allergens.

The IgE-Fabs and/or whole Ig according to the invention may be recombinantly produced.

In a third aspect, the invention relates to a diagnostic reagent comprising the IgE-Fabs and/or whole Ig according to the invention. Alternatively the reagent comprises the corresponding complete antibodies, and/or modified versions of said Fabs and/or antibodies.

In a fourth aspect, the invention relates to a diagnostic kit comprising the reagent mentioned above. The kit may be any conventional kit for performing an immunoassay.

In a fifth aspect, the invention relates to a vaccine against type I allergy, comprising the IgE-Fabs and/or whole Ig according to the invention.

A preferred use of Phl p 2-specific IgE-Fabs and/or whole Ig and the vaccine according to the invention is for passive immunotherapy of type I allergy. The use may be in preventive or therapeutic purpose.

Another use of Phl p 2-specific IgE-Fabs and/or whole Ig according to the invention is for diagnosing of type I allergy.

A further use of Phl p 2-specific IgE-Fabs and/or whole Ig according to the invention is for environmental allergen detection.

Yet a further use of f Phl p 2-specific IgE-Fabs and/or whole Ig according to the invention is for standardization of allergen extracts.

In order to obtain specific competitors of human origin which interfere with the IgE allergen interaction the inventors used the combinatorial library technique (14). An IgE combinatorial library was constructed from lymphocytes of a grass pollen allergic patient (15). The present invention provides human IgE Fabs with specificity for group 2 grass pollen allergens. The human IgE Fabs lack their constant region and therefore cannot activate effector cells to release biologically active mediators. The binding site of the IgE Fabs on group 2 allergens were mapped using recombinant fragments of the major timothy grass pollen allergen Phl p 2 and the crossreactivity of the IgE Fabs with group 2 allergens from different grass and corn species was investigated. Furthermore the Phl p 2-specific IgE Fabs are useful for the identification of group 2 allergen-containing pollen by particle blotting. By ELISA competition experiments, the ability of the IgE Fabs to block binding of grass pollen allergic patients IgE antibodies to Phl p 2 was analyzed. The usefulness of the recombinant group 2-specific IgE Fabs for the detection of environmental allergen loads, the standardization of diagnostic and therapeutic allergen extracts and for passive therapy of grass pollen allergy are discussed.

Detailed description of the invention**MATERIALS AND METHODS****Biological materials, patients sera, antibodies**

Pollen from sweet vernal grass, oat, Bermuda grass, rye grass, common reed, Kentucky Bluegrass, rye, wheat and maize were purchased from Allergon (Välinge, Sweden). Sera were collected from grass pollen-allergic patients who were characterized by case history, skin prick testing, RAST, and by testing with recombinant grass pollen allergens as described (16). Sera from non allergic individuals were included as negative controls. ^{125}I -labeled anti-human IgE antibodies (RAST) were obtained from Pharmacia (Pharmacia & Upjohn Diagnostics AB, Uppsala, Sweden).

E.coli strain XL1-Blue was obtained from Stratagene (La Jolla, CA), and plasmid pComb3H representing a modification of plasmid pComb3 (17) was kindly provided by Carlos F. Barbas, Scripps (LaJolla, CA). Alkaline phosphatase-coupled goat anti-human Fab and goat anti-mouse Fab antisera were purchased from Pierce (Rockford, IL).

Sequence analysis of the cDNAs coding for IgE Fds and light chains

Three phage clones expressing antibody fragments with specificity for Phl p 2 were isolated by panning to rPhl p 2 as described (15). All three clones were checked for the production of Phl p 2-specific Fabs by ELISA and for the correct insertion of cDNAs coding for the heavy chain fragments and the light chains by restriction analysis before sequencing. Plasmid DNA was prepared from recombinant *E. coli* XL-1 Blue using Qiagen tips (Hilden, Germany). Both DNA strands were sequenced using ^{35}S -dCTP (DuPont NEN, Stevenage, UK) and a T7 polymerase sequencing kit (Pharmacia) by primer walking (18). Sequencing primers were obtained from MWG (MWG AG- Biotech, Ebersberg, Germany). The Phl p 2-specific DNA sequences of the heavy chain fragments and the light chains were compared with the germline sequences deposited in the V Base Sequence Directors (Tomlinson *et al.*, MRC Centre for Protein Engineering, Cambridge, UK).

Expression of rPhl p 2-specific Fabs in *E.coli*

E.coli XL1-Blue cells containing the rPhl p 2-specific Fab expressing pComb3H plasmids were grown in SB medium containing 50 µg/ml ampicillin at 37 °C up to O.D. 600nm 0.6-1. After induction with 1.5 mM IPTG, cells were incubated for four hours at 32°C. Induced *E.coli* were harvested by centrifugation at 5000 rpm for 20 min at 4 °C and supernatants were stored at -20 °C for ELISA analysis. Cells were resuspended in PBS containing 1 mM PMSF, homogenized with an ultraturrax (Ika, Stauffen, Germany) and centrifuged at 18,000 rpm for 20 min at 4 °C (extract). The extracts were tested in ELISA assays for their binding capacity to rPhl p 2 as described (15).

Expression of recombinant fragments of the Phl p 2 allergen for mapping of the binding sites of the human IgE Fabs

Lambda gt11 phage clones expressing β-galactosidase fused complete Phl p 2 and Phl p 2 fragments were generated as described (8). *E.coli* Y1090 were plated as confluent lawn onto LB plates containing 100mg/l ampicillin (19). Two µl aliquots of phage lysates containing $> 10^6$ plaque-forming units of each phage clone were dotted onto the *E. coli* lawn in defined order and plates were incubated at 43°C until plaques became visible. The synthesis of recombinant protein was induced by overlay with 10 mM IPTG-soaked nitrocellulose filters (Schleicher& Schuell, Dassel, Germany) for additional 4 hours. The clones which reacted with the IgE Fabs were identified by immunoscreening. For this purpose filters were washed twice for 5 min and once for 30 min with TBST containing 0.5% w/v BSA at roomtemperature and then probed overnight with *E. coli* extracts containing anti-Phl p 2 Fab and, for control purposes, with extracts from *E. coli* transformed with the empty pComb 3H plasmid at 4 °C. After washing, the Fabs were detected with an alkaline phosphatase-coupled goat anti-human Fab antiserum diluted 1:5000 in TBST/0.5% w/v BSA.

Preparation of natural pollen extracts; identification of group 2 allergens by immunoblotting

Hundred mg of pollen of each grass and corn species were resuspended separately in 5 ml SDS-sample buffer and homogenized with an ultraturrax (IKA, Stauffen, Germany) for 1 min, boiled for 5 min at 95 °C and centrifuged with 14500 rpm for 5 min to remove insoluble materials. Comparable amounts of protein extracts (100 µg[slot) were then separated by a 14% SDS-PAGE under reducing conditions, stained with Coomassie Brilliant Blue or blotted onto nitrocellulose (Schleicher & Schuell) (20-22).

Nitrocellulose membranes containing blotted pollen extracts from the different grass and corn species were blocked twice for 5 min and once for 30 min with TBST containing 0.5% w/v BSA at roomtemperature and then exposed overnight with bacterial extracts containing Phl p 2-specific IgE Fabs at 4 °C. After washing, membranes were incubated with an alkaline phosphatase-coupled goat anti-human Fab antiserum diluted 1:5000 in TBST/0.5% w/v BSA, respectively to detect bound Fabs.

Particle blotting

Pollen grains from sweet vernal grass, oat, Bermuda grass, rye grass, timothy grass, common reed, Kentucky Bluegrass, rye, wheat, maize and birch (control) were applied to a nitrocellulose membrane in defined order using toothpicks. Membranes were placed on water-soaked Whatman paper for half an hour to allow the release of allergens. Released proteins were detected with Ponceau S (Boehringer, Mannheim, Germany) as described (19). Group 2 allergens were detected with Phl p 2-specific IgE Fabsas described for the immunoblotting. For the identification of pollen grains releasing the major birch pollen allergen Bet v 1 a recombinant mouse anti-Bet v 1 Fab was used which was detected with an alkaline phosphatase-conjugated goat anti-mouse Fab antiserum (Pierce).

IgE competition experiments

The ability of Phl p 2-specific IgE Fabs to inhibit the binding of grass pollen allergic patients IgE antibodies to Phl p 2 was studied by immunoblot competition experiments. Nitrocellulose strips containing equal aliquots of blotted rPhl p 2 (1 μ g/cm) were blocked twice for 5 min and once for 30 min in buffer A (50 mM sodium phosphate buffer, pH 7.4, containing 0.5% w/v BSA, 0.5% v/v Tween^{*}20 and 0.05% w/v NaN₃) at roomtemperature and then preincubated overnight with bacterial extracts containing Phl p 2 specific IgE Fabs and, for control purposes, with bacterial extracts containing an anti-Phl p 5 IgE Fabs (both at a concentration 5 μ g/ml) at 4 °C. After washing, strips were incubated overnight with sera from grass pollen allergic patients diluted 1: 5 in buffer A at 4°C. Bound IgE antibodies were detected with ¹²⁵I-labeled anti-human IgE antibodies (RAST, Pharmacia) and the amount of bound IgE antibodies was quantified by gamma-counting in a gamma counter (1277 Gammamaster, LKB, Wallac). All experiments were performed as duplicates with variations of less than 10% and results represent mean values. The percentage inhibition of IgE binding was calculated from the mean cpm value measured with or without addition of competing Fab. Percentage inhibition = $100 - \frac{\text{cpm}_{\text{Fab}}}{\text{cpm}_{\text{control}}} \times 100$.

RESULTS

The results will be discussed below in association with the accompanying sequence listing and drawings:

*Trademark

Figure 1. Comparision of the variable heavy chain (Fig. 1A) and light chain (Fig. 1B) DNA sequence of clone 94 with the closest related germline sequences (accession numbers are printed on the left margins). The positions of the CDRs and FRs are indicated. Nucleotides are grouped in aa-encoding triplets and identical nucleotides are displayed by dashes.

Figure 2. Mapping of the binding site of the Phl p 2-specific human IgE Fab on the Phl p 2 allergen. Overview of the recombinant Phl p 2 fragments comprising the N-terminal 64 amino acids and the C-terminal 69 amino acids (Figure 2A). Figure 2B shows a ribbon representation of the three-dimensional structure of the Phl p 2 allergen in which the N-terminal and C-terminal fragment has been indicated. Figure 2C: Binding of the clone 94-derived IgE Fab to nitrocellulose filters containing complete rPhl p 2 (1), the N-terminal (2), C-terminal (3) Phl p 2-derived fragments and β -gal alone (4). For control purposes, filter-bound clones were exposed to bacterial extracts from *E. coli* transformed with empty plasmid (pComb3H).

Figure 3. rPhl p 2-specific IgE-Fabs crossreact with natural group 2 allergens from different grasses. rPhl p 2-specific IgE Fabs were tested for reactivity with nitrocellulose-blotted grass pollen extracts (Ant o: sweet vernal grass; Ave s: oat; Cyn d: Bermuda grass; Lol p: rye grass; Phr c: common reed; Poa p: Kentucky Blue grass; Sec c: rye; Tri s: wheat; Zea m:

maize, *Phl p*: timothy grass). The position of the 14.3 kDa marker is indicated with an arrow on the right margin.

Figure 4. Detection of pollen grains containing group 2 allergens by particle blotting. Pollen grains from ten different monocots (*Ant o*: sweet vernal grass; *Ave s*: oat; *Cyn d*: bermuda grass; *Lol p*: rye grass; *Phl p*: timothy grass; *Phr c*: common reed; *Poa p*: Kentucky Blue grass; *Sec c*: rye; *Tri s*: wheat; *Zea m*: maize) and birch (*Bet v*) were dotted to nitrocellulose. Released proteins were stained with Ponceau S (A). Group 2 allergens were detected with *Phl p* 2-specific IgE Fabs (B), the major birch pollen allergen, *Bet v* 1, with specific Fabs (C). The three *Phl p* 2-specific IgE Fabs contain closely related heavy chain fragments which have recombined with different light chains: sequence homology with autoantibodies

Framework as well as complementarity determining regions of the three heavy chain fragments (clones 94, 60, 100) were of equal size. (SEQ ID NO. 1-3) and their VH regions showed the highest similarity with members of the VH4 family (e. g., accession number: U71106; 23). Alignment of the cDNAs coding for the heavy chain variable regions of the three clones shows that they differ only in few nucleotides (27 out of 342 bp, 8% for clone 94 versus clone 60; 18 out of 342 bp, 5% for clone 94 versus clone 100; 9 out of 342 bp, 3% for clone 60 versus clone 100). The nucleotide exchanges were equally distributed over the complete variable region including frameworks and CDRs (SEQ ID NO. 1-3).

Sequence analysis of the light chain cDNAs revealed that they all belonged to the kappa family. The sequence comparison of the three light chains showed much greater variation than was observed among the heavy chains (SEQ ID NO. 4-6). Most of the nucleotide exchanges were observed in the CDR1 (9%-33%) and in the CDR3 (25%-33%).

A comparison of the deduced amino acid sequences of the variable regions of the heavy chain fragments of the three r*Phl p* 2-specific IgE Fab clones is displayed in SEQ ID NO. 7-9. Clones 60 and 100 are very similar (95% sequence identity) whereas a more moderate sequence identity of 86% and 88% was observed between clones 60 and 94, and

between clones 94 and 100, respectively. The few amino acid exchanges were sometimes not conservative ones and equally distributed over the framework and complementarity determining regions of the three clones (Fig. 2A). When compared with known human variable regions a surprising sequence similarity was found to a human IgM rheumatoid factor (accession number: Y14936; 24) (Fig. 2A) With exception of the CDR3 region which was completely different in sequence and length between the heavy chain fragments of the IgE Fabs and the rheumatoid factor, a comparable sequence identity was found for CDR1 and CDR2 as well as for all 4 framework regions of the IgE Fabs and the rheumatoid factor (SEQ ID NO. 7-9).

SEQ ID NO. 2B shows the alignment of the deduced amino acid sequences of the light chains of the three clones. The amino acid sequences of the three light chains showed a considerable sequence variation, particularly in the CDR1 (27-46%) and in the CDR3 (56%). The CDR2 regions differed only in one or two aa exchanges and also in framework regions only few amino acid exchanges were noted (<10% in FRW1, <14% in FRW2, <10% in FRW3) (SEQ ID NO. 10-12).

The three IgE Fab-derived light chains showed an interesting amino acid sequence similarity with light chains from human autoantibodies, one from a human anti-Rh (D) antibody (accession number: AF044462; 25) and two human rheumatoid factors (accession numbers S56199; S67059; 26, 27).

Somatic mutations in the variable regions of the IgE Fabs are indicative of an antigen-driven selection process

Fig. 1A shows the comparision of the DNA sequence of the variable region of the clone 94 heavy chain fragment with the closest related germline sequences (accession number: Z12365: V-genes, FR1- FR3; X97051: D-genes, CDR3; X86355: J-genes, CDR3+ FR4) (22-24). In total we found 26 nucleotide exchanges of which 11% (10/93) were found in the CDRs and 7% (16/243) were observed in the framework regions. Five of these mutations were silent whereas 18 mutations led to amino acid exchanges.

The comparision of the variable region DNA sequence of the clone 94 light chain with the most closely related germline sequences (accession number: X93627: V-genes, FR1-CDR3; J00242: CDR3+ FR4; 25, 26) is shown in Figure 1B. We found 18 nucleotide exchanges of which 11% (9/81) were located in the CDRs and 4% (9/228) occurred in the frame work regions. Most mutations were found in the CDR3.

A recombinant fragment comprising the N-terminal 64 amino acids of Phl p 2 contains the binding site for the IgE Fabs

In order to determine the binding site for the rPhl p 2-specific IgE Fabs, nitrocellulose-dotted complete β -gal-fused rPhl p 2 allergen (96 aa), a N-terminal rPhl p 2 fragment comprising the first 64 aa portion (1-64) and a 69 aa long C-terminal rPhl p 2 fragment (28-96 aa) were exposed to the Fabs (Fig. 2A). Fig. 2B shows a ribbon representation of the complete Phl p 2 allergen which is similar to an immunoglobulin domain and consists mainly of β -sheet structure. The N-terminal and C-terminal fragment have been indicated in the model (Fig. 2B). These two fragments were previously identified as IgE-reactive domains whereas smaller fragments did not show IgE binding capacity (8). As exemplified for clone 94, all three Phl p 2-specific IgE Fabs recognized the complete rPhl p 2 (1) and the N-terminal rPhl p 2 fragment (2) but did not bind to the C-terminal fragment (3) nor to λ gt 11 phage control proteins (4) (Fig. 2C). Bacterial extracts obtained from bacteria which were transformed with the empty pComb3H plasmid did not react with any of the dotted proteins (Fig. 2C). No reactivity of the Phl p 2-specific IgE Fabs with the smaller Phl p 2 fragments described previously (8) was observed (data not shown).

Anti-Phl p 2 IgE Fabs crossreact with natural group 2 allergens from 7 grass and corn species and identify group 2 allergen-containing pollen by particle blotting

In order to investigate whether the recombinant human IgE Fabs crossreacted with natural group 2 allergens from different grass and corn species, nitrocellulose-blotted natural pollen extracts from several grass and corn species were tested (Fig. 3). The IgE Fabs

reacted strongly with group 2 allergens in sweet vernal grass, rye grass, Kentucky Bluegrass, rye and wheat. Only weak reactivity was observed with oat and common reed. No reactivity was seen with pollen extracts from monocots reportedly lacking or containing low levels of group 2 allergens (Bermuda grass, maize) (16).

Environmental measurements of pollen allergen loads are currently performed by air sampling and analysis of pollen morphology. We demonstrate that Phl p 2-specific Fabs can be used for the immunological identification of pollen grains containing group 2 allergens by particle blotting (Fig. 4). Membran-bound pollen grains from ten different grass species and birch released proteins after hydration which were stained with Ponceau S (Fig. 4A). Phl p 2-specific Fabs identified exclusively grass pollen grains containing group 2 allergens (sweet vernal grass, rye grass, Kentucky Bluegrass, rye, wheat and oat) (Fig. 4B). A mouse Fab with specificity for the major birch pollen allergen, Bet v 1, reacted only with birch pollen confirming the specificity of the assay (Fig. 4C).

Phl p 2-specific IgE Fabs inhibit binding of grass pollen allergic patients IgE antibodies to Phl p 2

Table 1 displays the quantification of IgE binding of sera from 27 grass pollen allergic patients to nitrocellulose-blotted rPhl p 2 which was preincubated with Phl p 2-specific IgE Fabs versus preincubation with Phl p 5-specific IgE Fabs (control) (Table 1). In 14 sera (52%) preincubation with Phl p 2-specific IgE Fabs reduced serum IgE binding > 50% (Table 1). In 10 sera (38%) the decrease of IgE binding was between 30-50% and in the remaining 3 sera (10%) a reduction of IgE binding between 22-29% could be achieved (Table 1). An average inhibition of IgE binding to Phl p 2 in range of 52% was achieved when Phl p 2 was preincubated with Phl p 2-specific IgE Fabs (Table 1).

Table 1. IgE Fabs inhibit the binding of allergic patients' IgE to rPhl p 2. Sera from 27 grass pollen allergic patients (#1-27) were exposed to nitrocellulose-blotted rPhl p 2 which has been preincubated with Phl p 2-specific IgE Fabs (column A) or with control proteins (column B). The cpm values corresponding to the amount of bound IgE antibodies are displayed in columns A and B. The third column shows the percentage of inhibition of IgE binding. The mean inhibition of IgE binding is displayed at the bottom of the third column.

Patient No.	cpm <u>with</u> <u>without</u> preincubation with Phl p 2-specific Fab	% of reduction
1	859.2	1389.4
2	406.5	2570.5
3	93.3	222.7
4	150.7	228.7
5	734.1	1222.8
6	895.5	4240
7	6482.3	17914.2
8	130.8	253.1
9	293.5	523.5
10	1508.4	4274.9
11	2238	4520.1
12	1088.5	1779.7
13	855.9	1423.7
14	194.6	313
15	252.4	1014.6
16	312.5	448.4
17	1350.3	3505.3
18	140.4	387.6
19	1343.3	3485.5
20	129	416.4
21	704.4	1161.7
22	122.5	173.5
23	1707.4	2360.6
24	600.6	2036.8
25	3495	4470.6
26	1128.9	3634.8
27	426.4	1323.2

DISCUSSION

The present inventors report the molecular and immunological characterization of three human IgE antibody fragments with specificity for one of the most important environmental allergens, the major timothy grass pollen allergen, Phl p 2. The IgE Fabs were isolated from an IgE combinatorial library which was constructed from lymphocytes of a grass pollen allergic patient via panning to recombinant Phl p 2. Sequence analysis revealed that all three heavy chain fragments belonged to the VH4 family and were closely related to each other (23). While in the heavy chain variable regions the few amino acid sequence variations were equally distributed over the framework and complementarity determining regions, the kappa light chains were less closely related and showed significant sequence variations in the CDR1 and CDR3 domains. We have already previously found that IgE Fabs with specificity for the major timothy grass pollen allergen consisted of identical heavy chain fragments which had recombined with different light chains (15). Furthermore it has been demonstrated that the Phl p 5-specific IgE heavy chain fragments can be recombined with light chains from antibodies with different specificity but retain antigen-specificity (15).

Also our study indicates that similar heavy chain fragments can recombine with different light chains but retain specificity for the original allergen. Although we have no proof that exactly those heavy chain and light chain combinations which we isolated via the combinatorial library approach existed in the allergic patient used for construction of the library, the latter findings support the assumption that the specificity of certain IgE antibodies is dictated by the heavy chains and that promiscuous use of light chains is possible without loosing allergen specificity. In this context it is of note that all three IgE Fabs bound to the same recombinant fragment comprising the N-terminal 64 amino acids of Phl p 2.

The close sequence similarity of the heavy chain fragments as well as of the light chains of the Phl p 2-specific IgE Fabs with human autoantibodies (rheumatoid factors, anti Rh (D) antibodies) is of note in view of the fact that the recently determined three dimensional structure of Phl p 2 exhibited an unexpected similarity with immunoglobulin-like

domains occurring in man (8). So far we have no evidence that the IgE Fabs can react with human proteins but when tested with pollen extracts from a variety of grass and corn species we found extensive crossreactivity with group 2 allergens. The recombinant Phl p 2-specific IgE Fabs may therefore be used to determine loads of group 2 allergens in the environment and may thus be useful for preventive measures. Furthermore they may be used for the determination and standardization of group 2 allergens in natural allergen extracts currently used for diagnosis and treatment of grass pollen allergy. Our finding that Phl p 2-specific IgE Fabs reacted with a major epitope-containing domain of Phl p 2 and strongly (mean inhibition 52%) inhibited binding of grass pollen allergic patients (n=27) complete IgE antibodies to Phl p 2 indicates a therapeutic potential of the Fabs. If the Fabs can be attached to epithelial cells or antigen-presenting cells in the target organs of atopy it may even become possible to build up a stable defense line against intruding allergens and perhaps to target them directly into the proteolytic compartment of antigen presenting cells without activating effector cells. The latter approach may not only inactivate the allergen via proteolysis but may be also useful for the induction of a protective mucosal immunity.

REFERENCES

1. Kay, A.B. (1997). *Allergy and Allergic Diseases*, Blackwell Science, Oxford, U.K.
2. Segal, D.M., Taurog, J.D., and Metzger H. (1977). Dimeric immunoglobulin E serves as a unit signal for mast cell degranulation. *Proc. Natl. Acad. Sci. USA* **42**, 457-467
3. Ansari, A.A., Shenbagamurthi, P., and Marsh, D.G. (1989). Complete amino acid sequence of a *Lolium perenne* (perennial rye grass) pollen allergen, *Lol p II*. *J. Biol. Chem.* **264**, 11181-11185.
4. Ansari, A.A., Shenbagamurthi, P., and Marsh, D.G (1989). Complete primary structure of a *Lolium perenne* (perennial rye grass) pollen allergen, *Lol p III*: comparision with known *Lol p I* and *Lol p II* sequences. *Biochem.* **28**, 8665-8670.
5. Sidoli, A., Tamborini, E., Giuntini, I., Levi, S., Volonte, G., Paini, C., DeLalla, C., Siccardi, A.G., Baralle, F.E., Galliani, S., et al. (1993). Cloning, expression and immunological characterization of recombinant *Lolium perenne* allergen *Lol p II*. *J. Biol. Chem.* **268**, 21819-21825.
6. Dolecek, C., Vrtala, S., Laffer, S., Steinberger, P., Kraft, D., Scheiner, O., and Valenta, R. (1993). Molecular characterization of *Phl p II*, a major timothy grass (*Phleum pratense*) pollen allergen. *FEBS Lett.* **335**, 299-304
7. Roberts, A.M., Bevan, L.J., Flora, P.S., Jepson, I., and Walker, M.R. (1993). Nucleotide sequence of cDNA encoding the group II allergen of cocksfoot/orchard grass (*Dactylis glomerata*), *Dac g II*. *Allergy* **48**, 615-623.
8. De Marino, S., Castiglione Morelli, M.A., Fraternali, F., Tamborini, E., Musco, G., Vrtala, S., Dolecek, C., Arosio, P., Valenta, R., and Pastore, A. (1999). An immunoglobuline-like fold in a major plant allergen: The solution structure of *Phl p 2* from timothy grass pollen. *Structure* **7**, 943-952
9. Noon, L. (1911). Prophylactic inoculation against hay fever. *Lancet* **1**, 1572-1573

10. Bousquet, J., Lockey, R., Malling, H.J., and the WHO panel members. (1998). Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. *J. Allergy Clin. Immunol.* **102**, 558-562.
11. Durham, S.R., and Till, S.J. (1998). Immunological changes associated with allergen immunotherapy. *J. Allergy Clin. Immunol.* **102**, 157-164.
12. Cooke, R.A., Bernhard J.H., Hebard, S., and Stull, A. (1935). Serological evidence of immunity with co-existing sensitization in hay fever type of human allergy. *J. Exp. Med.* **62**, 733-750
13. Loveless, M.H. (1940). Immunological studies of pollinosis: I. The presence of 2 antibodies related to the same pollen-allergen in the serum of treated hay fever patients. *J. Immunol.* **38**, 25-50.
14. Huse, W.D., Sastry, L., Iverson, S.A., Kang, A.S., Alting-Mees, M., Burton, D., Benkovic, S.J., and Lerner R.A. (1989). generation of a large repertoire in phage lambda. *Science* **246**, 1275-1281.
15. Steinberger, P., Kraft, D., and Valenta, R. (1996). Construction of a combinatorial IgE library from an allergic patient. *J. Biol. Chem.* **271**, 10967-10972
16. Niederberger, V., Laffer, S., Fröschl, R., Kraft, D., Rumpold, H., Kapiotis, S., Valenta, R., and Spitzauer, S. (1998). IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5 and Bet v 2) account for a high percentage of grass pollen-specific IgE. *J. Allergy Clin. Immunol.* **101**, 258-264
17. Barbas, C.F., III, Kang, A.S., Lerner, R.A., and Benkovic, S.J. (1991). Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. *Proc. Natl. Acad. Sci. USA* **88**, 7978-7982
18. Sanger, F., Nicklen, S., and Coulson, A.R. (1977). DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA* **74**, 5463-5467
19. Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989) *Molecular cloning: A laboratory manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.

20. Bradford, M.M. (1976). A rapid sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **72**, 248-254
21. Fling, S.P., and Gregerson, D.S. (1986). Peptid and protein molecular weight determination by electrophoresis using a high molarity Tris buffer system without urea. *Anal. Biochem.* **155**, 83-88
22. Towbin, H., Staehelin, T., and Gordon, J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc. Natl. Acad. Sci.* **76**, 4350-4354
23. Fais, F., Sellars, B., Ghiotto F., Yan, X.J., Dono, M., Allen, S.L., Budman, D., Dittmar, K., Kolitz, J., Lichtman, S., Schulman, P., Schuster, M., Vinciguerra, V., Rai, K., Stevenson, F.K., Gregersen, P.K., Ferranini, M., and Chiarazzi, N. (1996). Examples of *in vivo* isotype class switching in IgM+ chronic lymphocytic leukemia B cells. *J. Clin. Invest.* **98**, 1659-1966
24. Williams, D.G., Mayes, S.P., and Mageed R.A. (1999). Rheumatoid factors isotype switch and somatic mutation variants within rheumatoid arthritis synovium. *Immunol.* **98**, 123-136
25. Siegel, D.L., Chang, T.Y., Russell, S.L., and Bunya, V.Y. (1997). Isolation of cell surface-specific human monoclonal antibodies using phage display and magnetically-activated cell sorting: applications in immunohematology. *J. Immunol. Methods* **206**, 73-85
26. Ermel, R.W., Kenny, T.P., Chen, P.P., and Robbins, D.L. (1993). Molecular analysis of rheumatoid factors derived from rheumatoid synovium suggests an antigen-driven response in inflamed joints. *Arthritis Rheum.* **36**, 380-388
27. Martin, T., Crouzier, R., Blaison, G., Levallois, H., and Pasquali, J.L. (1993). A minor group of rheumatoid factors isolated from a patient with rheumatoid arthritis is derived from somatically mutated V_k1 genes further evidence that

rheumatoid factors during autoimmune diseases undergo an antigen driven maturation. *Autoimmun.* **15**, 163-170

28. Tomlinson, I.M., Walter, G., Marks, J.D., Llewelyn, M. B., and Winter, G. (1992). The repertoire of human VH sequences reveals about fifty groups of VH segments with different hypervariable loops. *J. Mol. Biol.* **227**, 776-798
29. Ravetch, J. V., Siebenlist, U., Karsmeyer, S., Waldmann, T., and Leder, P. (1981). Structure of human immunoglobulin mu locus: Characerization of embryonic and rearranged J+ D genes. *Cell* **27**, 583-591
30. Mattila, P.S., Schugk, J., Wu, H., and Makela, O. (1995). Extensive allelic sequence variation in the J region of the human immunoglobulin heavy chain locus. *Eur. J. Immunol.* **25**, 2578-2582
31. Cox, J.P., Tomlinson, I.M., and Winter, G. (1994). A directory of human germ-line V kappa segments reveals a strong bias in their usage. *Eur. J. Immunol.* **24**, 827-836.
32. Hieter, P.A., Maizel, J. V. Jr., and Leder, P. (1982). Evolution of human immunoglobulin kappa J region genes. *J. Biol. Chem.* **257**, 1516-1522

SEQUENCE LISTING

<110> Pharmacia Diagnostics AB

<120> Group 2 allergen specific IgE-fabs and IGG molecules and use thereof

<130> 08-897880CA

<140> 2,429,636

<141> 2001-12-27

<150> 0004892-6

<151> 2000-12-29

<160> 12

<170> PatentIn version 3.1

<210> 1

<211> 342

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Clone 94 heavy chain

Nucleotides 1-6 represent restriction sites for Xho I and Sac I

Nucleotides 7-78 represent FR1

Nucleotides 79-99 represent CDR1

<220>

<221> misc_feature

<223> Nucleotides 100-123 represent FR2

Nucleotides 134-141 represent FR3

Nucleotides 142-189 represent CDR2

Nucleotides 190-285 represent FR3

<220>

<221> misc_feature

<223> Nucleotides 286-309 represent CDR3

Nucleotides 310-342 represent FR4

<400> 1

ctcgagtctg gcccaggact ggtgaaggct gcacagaccc tgtccctcag ctgcgctgtc 60

tctggcggct ccatccgcag tggtggttac tactggagtt ggatccgcca acaccagg 120

aaggcctgg agtggattgg gtacatctat cacagtggaa acacctacta caacccgtcc	180
ctcaagagtc gaattgccat gtcggtagac acgtctgaga acaagttctc cctgaggctg	240
aactctgtga ctgccgcgga cacggccgtg tattactgtg cgaggtaga tggctacact	300
ttggacatct gggccaggg aaccctggtc accgtctcct ca	342

<210> 2

<211> 342

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Clone 60 heavy chain

Nucleotides 1-6 represent restriction sites for Xho I and Sac I

Nucleotides 7-78 represent FR1

Nucleotides 79-99 represent CDR1

<220>

<221> misc_feature

<223> Nucleotides 100-123 represent FR2

Nucleotides 134-141 represent FR3

Nucleotides 142-189 represent CDR2

Nucleotides 190-285 represent FR3

<220>

<221> misc_feature

<223> Nucleotides 286-309 represent CDR3

Nucleotides 310-342 represent FR4

<400> 2

ctcgagtctg gcccaggact ggtgaaggct tcacagaccc tgtccctcac ctgcactgtc	60
tctggggct ccatccgcag tgggggttat tattggagtt gggccgcga gcctccaggg	120
aaggcctgg agtggatcg caacatctat cacagtggca acacctacta caacccgtcc	180
ctcaagagtc gaattaccat gtcagtagac acgtctaaga accacttctc cctgagactg	240
acctctgtga ctgccgcgga cacggccgtc tattactgtg cgccgtcaga tgggtatact	300
ttggacaact gggccaggg aaccctggtc accgtctcct ca	342

<210> 3

<211> 342

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Clone 100 heavy chain

Nucleotides 1-6 represent restriction sites for Xho I and Sac I

Nucleotides 7-78 represent FR1

Nucleotides 79-99 represent CDR1

<220>

<221> misc_feature

<223> Nucleotides 100-123 represent FR2

Nucleotides 134-141 represent FR3

Nucleotides 142-189 represent CDR2

Nucleotides 190-285 represent FR3

<220>

<221> misc_feature

<223> Nucleotides 286-309 represent CDR3

Nucleotides 310-342 represent FR4

<400> 3

ctcgagtctg gcccaggact ggtgaaggct tcacagaccc tgtccctcac ctgcactgtc 60

tctggtggtt ccatccgcag tggtggttat tactggagtt ggatccgcca gcctccaggg 120

aagggcctgg agtggatcgg gtacatctat cacagtggca acacctacta caacccgtcc 180

ctcaagagtc gagttaccat gtcagtagac acgtctaaga accacttctc cctgaggctg 240

agctctgtga ctgccgcgga cacggccgtg tattactgtg cgaggtcaga tgggtacact 300

ttggacaact ggggccaggg aaccctggtc accgtctcct ca 342

<210> 4

<211> 318

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Clone 94 light chain

Nucleotides 1-6 represent restriction sites for Xho I and Sac I

Nucleotides 7-63 represent FR1

Nucleotides 64-96 represent CDR1

<220>

<221> misc_feature

<223> Nucleotides 97-141 represent FR2
 Nucleotides 142-162 represent CDR2
 Nucleotides 163-258 represent FR3
 Nucleotides 259-285 represent CDR3

<220>

<221> misc_feature

<223> Nucleotides 286-318 represent FR4

<400> 4
 gagctcaactc agtctccatc ctccctgtct gcatctgtgg gagacagagt caccatcagt 60
 tgccgggcaa gtcagagaat taacacctat ttaaatttgtt atcagcataa accaggaa 120
 gcccctaagc tcctgatcta tgctgcattc agtttgc当地 gtggggtccc atcaaggttc 180
 agtggcagtg gatatgggac agacttcact ctcaccatca gcagtctgca gcctgaagat 240
 tttgcaagtt actactgtca agagagtctc agtgccctcgt acactttgg ccaggggacc 300
 aaggtggaga tcaaacga 318

<210> 5

<211> 318

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Clone 60 light chain
 Nucleotides 1-6 represent restriction sites for Xho I and Sac I
 Nucleotides 7-63 represent FR1
 Nucleotides 64-96 represent CDR1

<220>

<221> misc_feature

<223> Nucleotides 97-141 represent FR2
 Nucleotides 142-162 represent CDR2
 Nucleotides 163-258 represent FR3
 Nucleotides 259-285 represent CDR3

<220>

<221> misc_feature

<223> Nucleotides 286-318 represent FR4

<400> 5

gagctcaccc agtctccatc ctccctgtct gcctctgttag gagacagagt caccatca	60
tgccgggcac gtcagagtat tagcacctat ttaaatttgtt atcagcagaa accgggaaag	120
gcccctaagc tcctgatctg gagtgcatcc aatttgcaaa gtggggtccc atccaggttc	180
agtggcagtg gatctggac agagttcaact ctcaccatca gcaatctgca acctgaagac	240
tttgcagtt actactgtca acagagttac actacccat atacccctgg ccctgggacc	300
aaactggaga tcaaacga	318

<210> 6

<211> 318

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Clone 100 light chain

Nucleotides 1-6 represent restriction sites for Xho I and Sac I

Nucleotides 7-63 represent FR1

Nucleotides 64-96 represent CDR1

<220>

<221> misc_feature

<223> Nucleotides 97-141 represent FR2

Nucleotides 142-162 represent CDR2

Nucleotides 163-258 represent FR3

Nucleotides 259-285 represent CDR3

<220>

<221> misc_feature

<223> Nucleotides 286-318 represent FR4

<400> 6

gagctcacgc agtctccatc ttccgtgtct gcacatctgttag gagacagagt caccataact	60
tgtcgggcga gtcagggtat tagcagttgg tttagcctgtt atcagcagaa accagggaaa	120
gcccctaaac tcctgatcta ttctgcatcc agtttgcaaa gtggggtccc gtcaaggttc	180
agcggcagtg gatctggac agatttcagt ctcaccatca gcagcctgca gcctgaagat	240

tctgcaactt actattgtca acaggctaac agtttccgt acactttgg ccaggggacc 300
 aaggtggaaa tcaaacga 318

<210> 7

<211> 114

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> Clone 94 heavy chain

Amino acids 1-26 represent FR1

Amino acids 27-33 represent CDR1

Amino acids 34-47 represent FR2

<220>

<221> MISC_FEATURE

<223> Amino acids 48-63 represent CDR2

Amino acids 64-95 represent FR3

Amino acids 96-103 represent CDR3

Amino acids 104-114 represent FR4

<400> 7

Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ala Gln Thr Leu Ser Leu
 1 5 10 15

Ser Cys Ala Val Ser Gly Gly Ser Ile Arg Ser Gly Gly Tyr Tyr Trp
 20 25 30

Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr
 35 40 45

Ile Tyr His Ser Gly Asn Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg
 50 55 60

Ile Ala Met Ser Val Asp Thr Ser Glu Asn Lys Phe Ser Leu Arg Leu
 65 70 75 80

Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu
 85 90 95

Asp Gly Tyr Thr Leu Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val
 100 105 110

Ser Ser

<210> 8
<211> 114
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Clone 60 heavy chain
Amino acids 1-26 represent FR1
Amino acids 27-33 represent CDR1
Amino acids 34-47 represent FR2

<220>
<221> MISC_FEATURE
<223> Amino acids 48-63 represent CDR2
Amino acids 64-95 represent FR3
Amino acids 96-103 represent CDR3
Amino acids 104-114 represent FR4

<400> 8

Leu	Glu	Ser	Gly	Pro	Gly	Leu	Val	Lys	Pro	Ser	Gln	Thr	Leu	Ser	Leu
1					5				10					15	

Thr	Cys	Thr	Val	Ser	Gly	Gly	Ser	Ile	Arg	Ser	Gly	Gly	Tyr	Tyr	Trp
							20						30		

Ser	Trp	Val	Arg	Gln	Pro	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Ile	Gly	Asn
							35				40		45		

Ile	Tyr	His	Ser	Gly	Asn	Thr	Tyr	Tyr	Ash	Pro	Ser	Leu	Lys	Ser	Arg
						50				55		60			

Ile	Thr	Met	Ser	Val	Asp	Thr	Ser	Lys	Asn	His	Phe	Ser	Leu	Arg	Leu
					65				70		75		80		

Thr	Ser	Val	Thr	Ala	Ala	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala	Arg	Ser
						85			90			95			

Asp	Gly	Tyr	Thr	Leu	Asp	Asn	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val
							100		105			110			

Ser Ser

<210> 9
<211> 114
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Clone 100 heavy chain
Amino acids 1-26 represent FR1
Amino acids 27-33 represent CDR1
Amino acids 34-47 represent FR2

<220>
<221> MISC_FEATURE
<223> Amino acids 48-63 represent CDR2
Amino acids 64-95 represent FR3
Amino acids 96-103 represent CDR3
Amino acids 104-114 represent FR4

<400> 9
Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu
1 5 10 15
Thr Cys Thr Val Ser Gly Gly Ser Ile Arg Ser Gly Gly Tyr Tyr Trp
20 25 30
Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn
35 40 45
Ile Tyr His Ser Gly Asn Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg
50 55 60
Val Thr Met Ser Val Asp Thr Ser Lys Asn His Phe Ser Leu Arg Leu
65 70 75 80
Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser
85 90 95
Asp Gly Tyr Thr Leu Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser

<210> 10
<211> 106

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> Clone 94 light chain
 Amino acids 1-21 represent FR1
 Amino acids 22-32 represent CDR1
 Amino acids 33-47 represent FR2

<220>

<221> MISC_FEATURE

<223> Amino acids 48-54 represent CDR2
 Amino acids 55-86 represent FR3
 Amino acids 87-95 represent CDR3
 Amino acids 96-104 represent FR4

<400> 10

Glu Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
 1 5 10 15

Val Thr Ile Ser Cys Arg Ala Ser Gln Arg Ile Asn Thr Tyr Leu Asn
 20 25 30

Trp Tyr Gln His Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
 35 40 45

Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
 50 55 60

Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp
 65 70 75 80

Phe Ala Ser Tyr Tyr Cys Gln Glu Ser Leu Ser Ala Ser Tyr Thr Phe
 85 90 95

Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 11

<211> 106

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> Clone 60 light chain

Amino acids 1-21 represent FR1

Amino acids 22-32 represent CDR1

Amino acids 33-47 represent FR2

<220>

<221> MISC_FEATURE

<223> Amino acids 48-54 represent CDR2

Amino acids 55-86 represent FR3

Amino acids 87-95 represent CDR3

Amino acids 96-104 represent FR4

<400> 11

Glu	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly	Asp	Arg
1				5					10				15		

Val	Thr	Ile	Thr	Cys	Arg	Ala	Arg	Gln	Ser	Ile	Ser	Thr	Tyr	Leu	Asn
				20				25				30			

Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile	Trp	Ser
				35			40					45			

Ala	Ser	Asn	Leu	Gln	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	Ser	Gly
					55					60					

Ser	Gly	Thr	Glu	Phe	Thr	Leu	Thr	Ile	Ser	Asn	Leu	Gln	Pro	Glu	Asp
65				70				75				80			

Phe	Ala	Ser	Tyr	Tyr	Cys	Gln	Gln	Ser	Tyr	Thr	Thr	Leu	Tyr	Thr	Phe
					85			90				95			

Gly	Ser	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg						
				100				105							

<210> 12

<211> 106

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> Clone 100 light chain

Amino acids 1-21 represent FR1

Amino acids 22-32 represent CDR1

Amino acids 33-47 represent FR2

<220>

<221> MISC_FEATURE

<223> Amino acids 48-54 represent CDR2
Amino acids 55-86 represent FR3
Amino acids 87-95 represent CDR3
Amino acids 96-104 represent FR4

<400> 12

Glu Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg
1 5 10 15

Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala
20 25 30

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser
35 40 45

Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
50 55 60

Tyr Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp
65 70 75 80

Ser Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Tyr Thr Phe
85 90 95

Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105

WE CLAIM:

1. Grass pollen group 2 allergen specific human IgE Fabs comprising heavy chain and light chain variable region amino acid sequences as shown in SEQ ID NOS 7 and 10, 8 and 11, or 9 and 12.
2. Grass pollen group 2 allergen specific human IgE Fabs comprising heavy chain and light chain variable regions encoded by the nucleic acid sequences as shown in SEQ ID NOS 1 and 4, 2 and 5, or 3 and 6.
3. IgE-Fabs according to claims 1 or 2 which are specifically directed against Phl p 2.
4. IgE-Fabs according to any one of claims 1 to 3 which are recombinantly produced.
5. A diagnostic reagent comprising at least one of the IgE-Fabs according to any one of claims 1-4.
6. A diagnostic kit comprising the reagent according to claim 5 and at least one component conventionally used in an immunoassay kit.
7. Use of at least one of the IgE-Fabs according to any one of claims 1 to 4 for passive immunotherapy of type I allergy.
8. Use of at least one of the IgE-Fabs according to any one of claims 1 to 4 or reagent according to claim 5 for diagnosing of type I allergy.
9. Use of at least one of the IgE-Fabs according to any one of claims 1 to 4 for environmental allergen detection.
10. Use of at least one of the IgE-Fabs according to any one of claims 1 to 4 for standardization of allergen extracts.

11. Grass pollen group 2 allergen specific human IgG comprising the IgE Fab heavy chain and light chain variable region amino acid sequences as shown in SEQ ID NOS 7 and 10, 8 and 11, or 9 and 12.
12. IgG according to claim 11, which are specifically directed against Phl p 2.
13. IgG according to claims 11 or 12 which are recombinantly produced.
14. A diagnostic reagent comprising at least one IgG according to any one of claims 11 to 13.
15. A diagnostic kit comprising the reagent according to claim 14 and at least one component conventionally used in an immunoassay kit.
16. Use of at least one IgG according to any one of claims 11 to 13 for passive immunotherapy of type I allergy.
17. Use of at least one IgG according to any one of claims 11 to 13 or reagent according to claim 14 for diagnosing of type I allergy.
18. Use of at least one IgG according to any one of claims 11 to 13 for environmental allergen detection.
19. Use of at least one IgG according to any one of claims 11 to 13 for standardization of allergen extracts.

1/7

Fig. 1A

CDR2 CTC TAA GAG ACG TCT GAG AAC TTC CGA AGT TCG GTTA CGC ATT ATG AGC AAG CTC 365
FR3 GAG AAC TCC TCT GAG AAG CGA AGT TCG GTTA CGC ATT ATG AGC AAG CTC 365

1

Fig. 1B

94 ACT CAG TCT CCA TCC CTG TCT GCA TCT GTG GGA GAC AGA GTC ACC ATC AGT TGC
 X93627 --C ---

94 CGG GCA AGT CAG AGA ATT AAC ACC TAT TTA ATT
 X93627 ---

94 AAA GCC CCT AAG CTC CTG ATC TAT
 X93627 --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---

94 CCA TCA AGG TTC AGT GGC AGT GGA TAT GGG ACA GAC TTC ACT CTC ACC ATC AGC AGT
 X93627 --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---

94 CTG CAG CCT GAA GAT TTT GCA AGT TAC TGT
 X93627 --- --A --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---

94 TAC ACT TTT GGC CAG GGG ACC AAG GTG GAG ATC AAA CGA
 J00242 --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---

FR1

FR1

FR1

FR1

FR1

FR1

FR2

FR2

FR2

FR2

FR2

FR2

FR3

FR3

FR3

FR3

FR3

FR3

FR4

FR4

FR4

FR4

FR4

FR4

CDR1

CDR1

CDR1

CDR1

CDR1

CDR1

CDR2

CDR2

CDR2

CDR2

CDR2

CDR2

CDR3

CDR3

CDR3

CDR3

CDR3

CDR3

CDR4

CDR4

CDR4


CDR4

CDR4

CDR4


3/7

Fig. 2A





4/7

Fig. 2B



5/7

Fig. 2C

IgE-Fab α PhI p 2

pComb3H







Fig. 3



7/7


Fig. 4

B



A

<i>Ant o</i>	<i>Ave s</i>	<i>Cyn d</i>	<i>Lol p</i>
<i>Phl p</i>	<i>Phr c</i>	<i>Poa p</i>	<i>Sec c</i>



C